1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Market cap: $710.6M (2/08/2026)
Price: $17.53
Investor Presentation
Reports Third Quarter 2025 Financial Results
Announces Plan for Return of $375 Million in Excess Capital
Other Events
Announces Participation at Upcoming Healthcare Conferences
U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
Reports Second Quarter 2025 Financial Results
Q3
Q2
Q1
FY 2023
SC TO-I
Tender Offer Statement by Issuer
Registration of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Tender Offer Statement by Issuer